Back to search results

MRI-Guided Radiation for Prostate Cancer

This study is looking at a new way to give radiation treatment for prostate cancer. It uses MRI (magnetic resonance imaging) scans to help doctors decide where to give higher doses of radiation to cancer cells and lower doses to healthy areas of the prostate. You would receive daily radiation for 4 weeks, along with hormone therapy (Androgen Deprivation Therapy) for 6-24 months. The study is for adult men (18 years or older) with prostate cancer that can be seen on an MRI and has not spread. The main goal is to see if this approach improves your bowel-related quality of life 12 months after treatment. The study plans to enroll 60 participants, but its current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 60 men.
What's involved
You would receive radiation treatment daily (Monday-Friday) for 4 weeks. You would also receive Androgen Deprivation Therapy for 6-24 months.
Compensation
Not stated in the trial record.
Follow-up
Your bowel-related quality of life will be measured 12 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06171269

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life

Recruiting
NAAges 18+InterventionalTreatment
University of Chicago
~60 participants
Updated 2026-03-04 on ClinicalTrials.gov
What's tested:RadiationMRIAndrogen Deprivation Therapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Improvement in bowel related quality of life
Measured over 12 months after treatment

Conditions

Prostate Cancer

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Stanley Liauw · PRINCIPAL_INVESTIGATOR · University of Chicago

Who to contact

Clinical Trials Intake
[email protected]
1-855-702-8222
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult (≥ 18 years old) male patients with an ECOG Performance Status 0-2
Histologically-confirmed, MRI-visible prostate adenocarcinoma with NCCN intermediate- or high-risk disease1 without extra-pelvic metastasis.

Exclusion

Distant metastases
Prior active treatment for prostate cancer including radical prostatectomy, high-intensity focused ultrasound (HIFU), cryosurgery, ADT, or cytotoxic chemotherapy for treatment of prostate cancer. Patients with prostate cancer on active surveillance prior to the study are not excluded if they have not received active treatment.
Prior pelvic radiotherapy including brachytherapy.
Additional active concurrent malignancies (except localized cutaneous squamous or basal cell carcinomas).
Comorbid conditions that, in the opinion of the treating radiation oncologist, preclude the patient from safely receiving the protocol-specified treatment including RT and/or ADT.
Patients with contraindications to MRI including patients with ferromagnetic materials in their body (e.g. bioimplants, surgical hardware, shrapnel), patients who are unable to receive contrast due to history of allergy or impaired renal function (glomerular filtration rate \< 30 mil/min), and patients unable to tolerate MRI for other reasons (e.g. significant claustrophobia).
Patients for whom hydrogel or hyaluronic acid spacer will be placed.
Patients incapable of giving informed consent.
Patients who are unable to adhere to the experimental protocols for any reason.

What this trial measures

  • Improvement in bowel related quality of life12 months after treatment

    Decrease by at least 5 points in bowel related endpoints as measured by Expanded Prostate Cancer Index Composite 26 (EPIC-26) questionnaire.